PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Disease ReportsNon-small-cell lung carcinoma
MeSH D002289 - non-small-cell lung carcinoma
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
See list view
D002283:Bronchogenic carcinoma
0 Companies
0 Drugs
Success rate
D002289: 
Non-small-cell lung carcinoma
86 Companies
44 Drugs
$
Success rate
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
Accord HealthcareDocetaxel Docetaxel  2011-06-08   
Docetaxel Docetaxel Accord  2012-05-22   
Erlotinib Erlotinib  2020-07-02   
Gemcitabine Gemcitabine  2011-07-25   
Paclitaxel Paclitaxel  2004-11-12   
Pemetrexed Pemetrexed  2022-05-25   
Pemetrexed Pemetrexed Accord  2016-01-18   
Topotecan Topotecan  2013-06-26   
Irinotecan Irinotecan  2008-11-21   
Alembic PharmaceuticalsErlotinib Erlotinib  2021-07-08   
Paclitaxel Paclitaxel  2022-10-20   
Docetaxel Docetaxel  2023-02-28   
AllerganPemetrexed Armisarte (previously Pemetrexed Actavis)  2016-01-18   
Docetaxel Docetaxel  2013-04-12   
Gefitinib Gefitinib  2023-04-26   
Gemcitabine Gemcitabine  2011-07-25   
Paclitaxel Paclitaxel  2009-12-09   
Pemetrexed Pemetrexed  2020-08-21   
Topotecan Potactasol  2011-01-06   
Topotecan Topotecan  2010-12-02   
Topotecan Topotecan Actavis  2009-07-24   
Vinorelbine Vinorelbine  2009-07-22   
Irinotecan Irinotecan  2008-02-27   
American RegentGemcitabine Gemcitabine  2013-05-07   
Paclitaxel Paclitaxel  2022-07-27   
AmgenSotorasib Lumakras 2038-05-21 2021-05-28   
Sotorasib Lumykras  2022-01-06   
Bevacizumab Mvasi  2017-09-14   
Amneal PharmaceuticalsBevacizumab Alymsys  2022-04-13   
Docetaxel Docetaxel  2018-01-19   
Pemetrexed Pemetrexed  2022-08-04   
ApotexDocetaxel Docetaxel  2012-01-11   
Erlotinib Erlotinib  2019-11-05   
Gefitinib Gefitinib  2022-09-23   
Gemcitabine Gemcitabine  2017-05-23   
Pemetrexed Pemetrexed  2022-05-25   
AstraZenecaDurvalumab Imfinzi  2018-09-21 $2,128 M Q2/22-Q2/25 
Gefitinib Iressa  2003-05-05 $207 M Q4/20-Q2/22 
Osimertinib Tagrisso 2032-07-25 2015-11-13 $3,291 M Q2/22-Q2/25 
Tremelimumab Tremelimumab AstraZeneca  2023-02-20   
Barr PharmaceuticalsHydroxyurea Hydroxyurea  1998-07-30   
1
2
3
4
5
6
...
9
>
Clinical Trials
Historical Success Rate
Phase 1
80%
257/323
Phase 2
40%
155/389
Phase 3
40%
97/240
Approved: 57Overall Success rate: 13%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Accord Healthcare
Gemcitabine
Allergan
Paclitaxel,
Docetaxel,
Aglatimagene besadenovec,
Bevifimod,
Nepidermin,
Globulin, immune,
Docetaxol,
Taxane
American Regent
Paclitaxel,
Paclitaxel docosahexaenoic acid,
Icosapent,
Doconexent,
Nepidermin,
Taxane
Amgen
Bevacizumab,
Sotorasib,
Benzocaine,
Melarsoprol,
Rilotumumab,
Motesanib,
Lenograstim,
Ganitumab,
Trebananib,
Doconexent,
Molgramostim,
Serine,
Bevifimod,
CONATUMUMAB,
Doxecitine,
Dulanermin,
Nepidermin,
Telbermin,
Troxerutin,
Insulin,
Globulin, immune,
Amg531,
Krestin,
Nerofe,
Viaject,
Mk3475,
Folinoral,
Histone-arginine methyltransferase carm1,
Gemcis,
Surlorian,
Docetaxol,
Taxane,
IDE397,
Rhuepo
AstraZeneca
Durvalumab,
Osimertinib,
Gefitinib,
Tremelimumab,
Benzocaine,
Docusate,
Fluorodopa f-18,
Monalizumab,
Oleclumab,
Domvanalimab,
Savolitinib,
Camizestrant,
Sitravatinib,
Gilvetmab,
Zorifertinib,
Itacitinib,
Aglatimagene besadenovec,
Cediranib,
Methionine,
Lenograstim,
Patritumab,
Saracatinib,
Zibotentan,
Glutamic acid,
Edrecolomab,
Doconexent,
Lornoxicam,
Alfacalcidol,
Cyproterone,
Molgramostim,
ADAVOSERTIB,
Ceralasertib,
Patritumab deruxtecan,
Serine,
Docusate sodium,
ABEQUOLIXRON,
Aspartame,
Bevifimod,
DANVATIRSEN,
Doxecitine,
IMARADENANT,
Nadide,
Naptumomab estafenatox,
Nepidermin,
Polyglycolic acid,
SAPITINIB,
Telbermin,
Tiratricol,
Troxerutin,
VACTOSERTIB,
Vilobelimab,
VISTUSERTIB,
Retinol,
D-glutamate,
Cyproterone acetate,
Fludeoxyglucose f-18,
Globulin, immune,
Bos taurus adrenal cortex corticosteroids,
Foster,
Sym-023,
Rilvegostomig,
AZD9592,
Lactams,
Mk3475,
Azd8853,
Pd0332991,
Ocx-0191,
Histone-arginine methyltransferase carm1,
AZD-1305,
AZD7789,
Curcumin,
Gemcis,
INTRACONAZOLE,
Olomorasib,
Surlorian,
AZD-1480,
Docetaxol,
Hidroxicloroquina,
Taxane,
Azd-4785,
Isoxaflutole,
Saffron
Boehringer Ingelheim
Nintedanib,
Afatinib,
Nintedanib esylate,
Fluorodopa f-18,
Gilvetmab,
Volasertib,
Glutamic acid,
Edrecolomab,
Aspartame,
Bevifimod,
CIMAGLERMIN ALFA,
Fenamole,
Nepidermin,
Polyglycolic acid,
XENTUZUMAB,
Retinol,
D-glutamate,
Fludeoxyglucose f-18,
Globulin, immune,
Bos taurus adrenal cortex corticosteroids,
Mk3475,
Histone-arginine methyltransferase carm1,
Gemcis,
Microgynon,
Surlorian,
Docetaxol,
Taxane
Bristol Myers Squibb
Nivolumab,
Paclitaxel,
Ipilimumab,
Hyaluronidase,
Relatlimab,
Adagrasib,
Hyaluronidase (human recombinant),
Benzocaine,
Docusate,
Fluorodopa f-18,
Bempegaldesleukin,
Sitravatinib,
Cilmostim,
Lucitanib,
Gilvetmab,
Linrodostat,
Entinostat,
Epacadostat,
Aglatimagene besadenovec,
Spartalizumab,
Guadecitabine,
Rigosertib,
Galunisertib,
Mesmulogene ancovacivec,
Brivanib alaninate,
Glutamic acid,
Doconexent,
Lornoxicam,
Taurine,
Molgramostim,
SOTIGALIMAB,
Catequentinib,
APRICOXIB,
Bevifimod,
CABIRALIZUMAB,
Doxecitine,
Edodekin alfa,
Farletuzumab,
Nepidermin,
PEGDINETANIB,
Polyglycolic acid,
Selicrelumab,
URELUMAB,
Vilobelimab,
Vorolanib,
Vusolimogene oderparepvec,
D-glutamate,
Fludeoxyglucose f-18,
Globulin, immune,
Foster,
Crystalloid,
Endocrine,
Nerofe,
Mk3475,
Mrtx1719,
Al3810,
Hiltonol,
Folinoral,
Histone-arginine methyltransferase carm1,
Gemcis,
UCPVAX,
ADG-106,
Surlorian,
Docetaxol,
Taxane
Celltrion
Bevacizumab,
Mk3475
Centus Biotherapeutics
Bevacizumab,
Bevifimod,
Globulin, immune,
Taxane
1
2
3
4
5
6
>
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use